Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Die finnische nationale Studie zur Erleichterung des Patientenzugangs zu zielgerichteten Krebsmedikamenten (FINPROVE)

9. November 2026 aktualisiert von: Katriina Jalkanen, Helsinki University Central Hospital

Die finnische nationale Studie zur Erleichterung des Patientenzugangs zu zielgerichteten Krebsmedikamenten zur Bestimmung der Wirksamkeit bei der Behandlung von fortgeschrittenen Krebserkrankungen mit bekanntem molekularem Profil

This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.

Studientyp

Interventionell

Einschreibung (Geschätzt)

250

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Kuopio, Finnland
        • Rekrutierung
        • Kuopio University Hospital
        • Kontakt:
          • Okko Kääriäinen, MD
      • Oulu, Finnland
        • Rekrutierung
        • Oulu University Hospital OYS Cancer Center
        • Kontakt:
          • Sanna Iivanainen, MD. PhD.
      • Tampere, Finnland
        • Rekrutierung
        • Tampere University Hospital Department of Oncology
        • Kontakt:
          • Minna Tanner, MD, PhD
    • Southwest Finland
      • Turku, Southwest Finland, Finnland
        • Rekrutierung
        • Turku University Hospital Cancer Centre
        • Kontakt:
          • Erika Alanne, MD, PhD
    • Uusimaa
      • Helsinki, Uusimaa, Finnland, 00029
        • Rekrutierung
        • Helsinki University Hospital Comprehensive Cancer Center
        • Kontakt:
          • Tanja Juslin
        • Hauptermittler:
          • Katriina Jalkanen, MD, PhD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 100 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.

  2. ECOG performance status 0-2

  3. Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:

    1. Absolute neutrophil count ≥ 1.5 x 109/l
    2. Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
    3. Platelets > 75 x 109/l (not applicable for hematological patients)
    4. Total bilirubin < 1.5 x ULN
    5. AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
    6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
  4. Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.

  5. Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.

  6. Patients must have a tumor profile for which treatment with one of the approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.

  7. A new (obtained ≤6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.

  8. Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.

  9. For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.

  10. Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.

Exclusion Criteria:

  1. Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.

  2. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:

    1. Patients suffering from CRPC are allowed to continue androgen deprivation therapy.
    2. Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.
  3. Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention

  4. Patient is pregnant or nursing.

  5. Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation. GMB patients apply additional exclusion criteria.

  6. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

  7. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

  8. Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible

  9. Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible

  10. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.

For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Alectinib

For patients with a molecular tumor profile that can potentially be targeted by alectinib.

ALK

Andere Namen:
  • Alecensa
Experimental: Cobimetinib

For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.

MEK1, MEK2

Andere Namen:
  • Cotellic
Experimental: Vismodegib

For patients with a molecular tumor profile that can potentially be targeted by vismodegib.

Hedgehog

Andere Namen:
  • Erivedge
Experimental: Trastuzumab+Pertuzumab

For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.

HER2

Andere Namen:
  • Phesgo
Experimental: Entrectinib

For patients with a molecular tumor profile that can potentially be targeted by entrectinib.

NTRK/ ROS1, ALK

Andere Namen:
  • Rozlytrek
Experimental: Atezolizumab

For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.

PD-L1

Andere Namen:
  • Tecentriq
Experimental: Vemurafenib

For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.

BRAF V600

Andere Namen:
  • Selboraf
Experimental: Regorafenib

For patients with a molecular tumor profile that can potentially be targeted by regorafenib.

KIT/BRAF, RET

Andere Namen:
  • Stivarga
Experimental: Apalutamide

For patients with a molecular tumor profile that can potentially be targeted by apalutamide.

AR

Andere Namen:
  • Erleada
Experimental: Abemaciclib

For patients with a molecular tumor profile that can potentially be targeted by abemaciclib.

CDK4/6

Andere Namen:
  • Verzenio
Experimental: Tepotinib

For patients with a molecular tumor profile that can potentially be targeted by tepotinib.

MET ex14

Andere Namen:
  • Tepmetko
Experimental: Dabrafenib

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib.

RAF

Andere Namen:
  • Tafinlar
Experimental: Trametinib

For patients with a molecular tumor profile that can potentially be targeted by trametinib.

MEK1, MEK2

Andere Namen:
  • Mekinist
Experimental: Dabrafenib+Trametinib

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination.

RAF, MEK1, MEK2

Andere Namen:
  • Tafinlanr+Mekinist
Experimental: Pemigatinib

For patients with a molecular tumor profile that can potentially be targeted by pemigatinib.

FGFR2

Andere Namen:
  • Pemazyre

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Disease control rate
Zeitfenster: 16 weeks

Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD)

16 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Duration of treatment
Zeitfenster: 5 years

Time on drug

5 years
Adverse Events
Zeitfenster: 5 years

Treatment-related grade ≥3 and serious adverse events

5 years
Overall response
Zeitfenster: 5 years

Best overall response (defined as patients by CR, PR, SD)

5 years
PFS
Zeitfenster: 5 years

Progression free survival

5 years
OS
Zeitfenster: 5 years

Overall survival

5 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Katriina Jalkanen, MD, PhD, Helsinki University Hospital Comprehensive Cancer Centre

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

10. Dezember 2021

Primärer Abschluss (Geschätzt)

25. November 2031

Studienabschluss (Geschätzt)

25. November 2032

Studienanmeldedaten

Zuerst eingereicht

3. Dezember 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. Dezember 2021

Zuerst gepostet (Tatsächlich)

16. Dezember 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

10. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • FINPROVE

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Investigators plan to share the clinical study report.

IPD-Sharing-Zeitrahmen

2026-2027

IPD-Sharing-Zugriffskriterien

Will be made available through European regulatory CTIS programme.

Art der unterstützenden IPD-Freigabeinformationen

  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .